Form 4: ATAI Life Sciences Executive Glenn Frank Short Reports Stock Transaction
SEC Form 4 Filing
Glenn Frank Short, Chief Scientific Officer of ATAI Life Sciences N.V., reports the vesting of restricted stock units and subsequent acquisition of common shares on March 14, 2025.
Summary
- On March 14, 2025, Glenn Frank Short, the Chief Scientific Officer of ATAI Life Sciences N.V., had restricted stock units vest.
- These vested restricted stock units converted into 32,500 common shares.
- Following this transaction, Short directly owns 55,494 common shares.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard reporting of stock transactions by an officer, neither particularly positive nor negative.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the Chief Scientific Officer in this case, engages in a transaction involving the company's securities. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine disclosure of insider activity.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of transaction: Restricted stock units vested and converted into common shares. |
| 03/19/2025 | Date of signature on the Form 4 filing. |
Keywords
ATAI Life Sciences, Glenn Frank Short, restricted stock units, common shares, Form 4, insider trading, beneficial ownership, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.